Sanofi India Q3 PAT Jumps 54% to ₹1,167 Crore

Key Quantitative Figures - Quarterly (Q3 FY26)

Revenue from Operations: ₹4,917 million (compared to ₹4,754 million in Q3 FY25)
Other Income: ₹55 million
Total Income: ₹4,972 million
Total Expenses: ₹3,395 million
Profit before exceptional item and tax: ₹1,577 million (compared to ₹1,296 million in Q3 FY25)
Exceptional Item: ₹0 (compared to an expense of ₹273 million in Q3 FY25, related to personnel separation costs)
Profit before tax: ₹1,577 million (compared to ₹1,023 million in Q3 FY25)
Income tax expense: ₹410 million (₹407 million current tax, ₹3 million deferred tax)
Profit for the period (PAT): ₹1,167 million (a 54% increase from ₹760 million in Q3 FY25)
Basic and diluted earnings per share (EPS): ₹50.67 (compared to ₹32.99 in Q3 FY25)
Paid-up equity share capital: ₹230 million (face value ₹10 per share)

Key Quantitative Figures - Nine Months (9M FY26)

Revenue from Operations: ₹14,017 million (compared to ₹14,176 million in 9M FY25)
Other Income: ₹161 million
Total Income: ₹14,178 million
Total Expenses: ₹10,099 million
Profit before exceptional item and tax: ₹4,079 million (compared to ₹3,890 million in 9M FY25)
Exceptional Item: ₹0 (compared to an expense of ₹273 million in 9M FY25)
Profit before tax: ₹4,079 million (compared to ₹3,617 million in 9M FY25)
Income tax expense: ₹1,051 million (₹1,047 million current tax, ₹4 million deferred tax)
Profit for the period (PAT): ₹3,028 million (compared to ₹2,650 million in 9M FY25)
Basic and diluted earnings per share (EPS): ₹131.48 (compared to ₹115.06 in 9M FY25)

Dividend Declaration

The Board declared an Interim Dividend of ₹75 per equity share (face value of ₹10 each) for the financial year 2026.
The Record Date for determining entitlement to the dividend is fixed as Thursday, 5th November 2026.
The dividend will be paid to members registered in the Company's Register of Members and beneficial owners as per details from NSDL and CDSL at the close of business on the record date.

Operational and Segment Performance (from Press Release)

Domestic Net Sales Growth: +2% Year-on-Year (YoY) for Q3 FY26.
Total Net Sales Growth: +4% YoY for Q3 FY26.
Diabetes Portfolio (Insulin) Growth: +9% YoY in Q3 FY26, cementing a 55% market share in the Diabetes Injectable segment. Key brands include Lantus®, Toujeo®, Apidra®, and Soliqua®.
Public Sector Business Growth: +85% surge in Q3 FY26, driven by new accounts for innovative analogue segments.
Export Sales: Delivered good double-digit growth.
Partnership Revenues (Cardiovascular, Oral anti-Diabetes, CNS): Were broadly stable in Q3 2026.
Profit before tax and exceptional items: ₹158 crores in Q3 FY26, a 22% increase from ₹130 crores in Q3 FY25.
Profit before tax margin: Improved to 34% in Q3 FY26 from 29% in Q3 FY25.
Operating expenses (employee cost + other expenses): Declined by 8% compared to Q3 FY25.

Management Commentary

Managing Director Deepak Arora stated that the diabetes business is growing in double digits quarter-on-quarter at a Year-to-Date (YTD) level and that PAT has also grown in double digits YTD. The acceleration in the public sector is widening access to innovative therapies. The company is celebrating 70 years in India and highlighted its corporate social responsibility initiatives:

The KIDS Program (Kids & Diabetes in School) has reached over 3,500 schools and educated 600,000 children in Goa, Uttar Pradesh, and Madhya Pradesh (MP). A pilot was launched in 2 districts of Bhopal (MP) with an aim to train 600+ teachers and ~40,000+ children in 2026.
Medical Mobile Units have screened for Non-Communicable Diseases (NCDs) and touched the lives of 780,000 beneficiaries across 11 districts of Maharashtra.

Regulatory and Compliance Details

The results were reviewed by the Audit Committee and approved by the Board of Directors on 29th October 2026.
The statutory auditors, Price Waterhouse & Co Chartered Accountants LLP, have issued a limited review report confirming the Statement is prepared in accordance with applicable Accounting Standards and SEBI Listing Regulations.
The results are prepared pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015.
An extract of the Financial Results will be published in newspapers as per Regulation 47.
The dividend declaration is pursuant to Regulation 42.
The financial results are available on the company's website.

Other Information

The Board meeting commenced at 2:30 p.m. and concluded at 4:45 p.m. on 29th October 2026.
The company has a single business segment: 'Pharmaceutical Business'.
The comparative figures for the year ended 31st December 2025 are audited.